High incidence of tumors in diabetic thrombin activatable fibrinolysis inhibitor and apolipoprotein E double-deficient mice

Journal of Thrombosis and Haemostasis

Volumn 8, Issue 11, 2010, Pages 2514-2522

  Beppu, T ^a   Gil Bernabe, P ^a   Boveda Ruiz, D ^a   D'alessandro Gabazza, C ^a   Matsuda, Y ^a   Toda, M ^a   Miyake, Y ^a   Shiraki, K ^a   Murata, M ^a   Murata, T ^b   Yano, Y ^a   Morser, J ^c   Gabazza, E C ^a   Takei, Y ^a  

^a MIE UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b SUZUKA GENERAL HOSPITAL   (Japan)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cancer; Carcinogenesis; Diabetes; Fibrinolysis; Strepto zotocin

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ALKALINE PHOSPHATASE; APOLIPOPROTEIN E; ASPARTATE AMINOTRANSFERASE; COMPLEMENT COMPONENT C5A; COMPLEMENT FACTOR D; CREATININE; SODIUM CHLORIDE; STREPTOZOCIN; THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR; TRANSFORMING GROWTH FACTOR BETA1;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOOD CLOTTING; CANCER INCIDENCE; COMPLEMENT BLOOD LEVEL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; GENOTYPE; KNOCKOUT MOUSE; LIVER CARCINOGENESIS; LIVER TUMOR; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; STREPTOZOCIN DIABETES; WILD TYPE;

ANIMALS; APOLIPOPROTEINS E; CARBOXYPEPTIDASE U; COMPLEMENT ACTIVATION; DIABETES MELLITUS, EXPERIMENTAL; FIBRINOLYSIS; GENOTYPE; HOMOZYGOTE; KIDNEY; LIVER; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NEOPLASMS, EXPERIMENTAL; STREPTOZOCIN; TIME FACTORS;

EID: 78149243002     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2010.04023.x     Document Type: Article

References (34)

1. Bouma BN, Mosnier LO. Thrombin activatable fibrinolysis inhibitor (TAFI) at the interface between coagulation and fibrinolysis. Pathophysiol Haemost Thromb 2003; 33: 375-81.
2. Bajzar L, Morser J, Nesheim M. TAFI, or plasma procarboxypeptidase B, couples the coagulation and fibrinolytic cascades through the thrombin-thrombomodulin complex. J Biol Chem 1996; 271: 16603-8.
3. Laurens N, Koolwijk P, De Maat MP. Fibrin structure and wound healing. J Thromb Haemost 2006; 4: 932-9.
4. Leung LL, Myles T, Nishimura T, Song JJ, Robinson WH. Regulation of tissue inflammation by thrombin-activatable carboxypeptidase B (or TAFI). Mol Immunol 2008; 45: 4080-3.
5. Morser J, Gabazza EC, Myles T, Leung LL. What has been learnt from the Thrombin Activatable Fibrinolysis Inhibitor (TAFI)-deficient mouse? J Thromb Haemost 2010; 8: 868-76.
6. Nagashima M, Yin ZF, Zhao L, White K, Zhu Y, Lasky N, Halks-Miller M, Broze GJ Jr, Fay WP, Morser J. Thrombin-activatable fibrinolysis inhibitor (TAFI) deficiency is compatible with murine life. J Clin Invest 2002; 109: 101-10.
7. Reijerkerk A, Meijers JC, Havik SR, Bouma BN, Voest EE, Gebbink MF. Tumor growth and metastasis are not affected in thrombin-activatable fibrinolysis inhibitor-deficient mice. J Thromb Haemost 2004; 2: 769-79.
8. Hatters DM, Peters-Libeu CA, Weisgraber KH. Apolipoprotein E structure: insights into function. Trends Biochem Sci 2006; 31: 445-54.
9. Song Y, Stampfer MJ, Liu S. Meta-analysis: apolipoprotein E genotypes and risk for coronary heart disease. Ann Intern Med 2004; 141: 137-47.
10. Stannard AK, Riddell DR, Bradley NJ, Hassall DG, Graham A, Owen JS. Apolipoprotein E and regulation of cytokine-induced cell adhesion molecule expression in endothelial cells. Atherosclerosis 1998; 139: 57-64.
11. Vogel T, Guo NH, Guy R, Drezlich N, Krutzsch HC, Blake DA, Panet A, Roberts DD. Apolipoprotein E: a potent inhibitor of endothelial and tumor cell proliferation. J Cell Biochem 1994; 54: 299-308.
12. Niemi M, Kervinen K, Kiviniemi H, Lukkarinen O, Kyllonen AP, Apaja-Sarkkinen M, Savolainen MJ, Kairaluoma MI, Kesaniemi YA. Apolipoprotein E phenotype, cholesterol and breast and prostate cancer. J Epidemiol Community Health 2000; 54: 938-9.
13. Slattery ML, Sweeney C, Murtaugh M, Ma KN, Potter JD, Levin TR, Samowitz W, Wolff R. Associations between apoE genotype and colon and rectal cancer. Carcinogenesis 2005; 26: 1422-9.
14. Watson MA, Gay L, Stebbings WS, Speakman CT, Bingham SA, Loktionov A. Apolipoprotein E gene polymorphism and colorectal cancer: gender-specific modulation of risk and prognosis. Clin Sci (Lond) 2003; 104: 537-45.
15. Lenzen S. The mechanisms of alloxan- and streptozotocin-induced diabetes. Diabetologia 2008; 51: 216-26.
16. Piedrahita JA, Zhang SH, Hagaman JR, Oliver PM, Maeda N. Generation of mice carrying a mutant apolipoprotein E gene inactivated by gene targeting in embryonic stem cells. Proc Natl Acad Sci USA 1992; 89: 4471-5.
17. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet 2001; 357: 539-45.
18. Bhuyan BK. The action of streptozotocin on mammalian cells. Cancer Res 1970; 30: 2017-23.
19. Hard GC. Identification of a high-frequency model for renal carcinoma by the induction of renal tumors in the mouse with a single dose of streptozotocin. Cancer Res 1985; 45: 703-8.
20. Kazumi T, Yoshino G, Fujii S, Baba S. Tumorigenic action of streptozotocin on the pancreas and kidney in male Wistar rats. Cancer Res 1978; 38: 2144-7.
21. Gruys ME, Back TC, Subleski J, Wiltrout TA, Lee JK, Schmidt L, Watanabe M, Stanyon R, Ward JM, Wigginton JM, Wiltrout RH. Induction of transplantable mouse renal cell cancers by streptozotocin: in vivo growth, metastases, and angiogenic phenotype. Cancer Res 2001; 61: 6255-63.
22. Rickles FR. Mechanisms of cancer-induced thrombosis in cancer. Pathophysiol Haemost Thromb 2006; 35: 103-10.
23. McMahon B, Kwaan HC. The plasminogen activator system and cancer. Pathophysiol Haemost Thromb 2008; 36: 184-94.
24. Hataji O, Taguchi O, Gabazza EC, Yuda H, D'Alessandro-Gabazza CN, Fujimoto H, Nishii Y, Hayashi T, Suzuki K, Adachi Y. Increased circulating levels of thrombin-activatable fibrinolysis inhibitor in lung cancer patients. Am J Hematol 2004; 76: 214-9.
25. Higuchi T, Nakamura T, Kakutani H, Ishii H. Thrombomodulin suppresses invasiveness of HT1080 tumor cells by reducing plasminogen activation on the cell surface through activation of thrombin-activatable fibrinolysis inhibitor. Biol Pharm Bull 2009; 32: 179-85.
26. Vairaktaris E, Yapijakis C, Nkenke E, Vassiliou S, Vylliotis A, Nixon AM, Derka S, Ragos V, Spyridonidou S, Tsigris C, Neukam FW, Patsouris E. The 1040C/T polymorphism influencing thermal stability and activity of thrombin activatable fibrinolysis inhibitor is associated with risk for oral cancer. Am J Hematol 2007; 82: 1010-2.
27. Rijken DC, Lijnen HR. New insights into the molecular mechanisms of the fibrinolytic system. J Thromb Haemost 2009; 7: 4-13.
28. Te Velde EA, Wagenaar GT, Reijerkerk A, Roose-Girma M, Borel Rinkes IH, Voest EE, Bouma BN, Gebbink MF, Meijers JC. Impaired healing of cutaneous wounds and colonic anastomoses in mice lacking thrombin-activatable fibrinolysis inhibitor. J Thromb Haemost 2003; 1: 2087-96.
29. Aggarwal BB, Shishodia S, Sandur SK, Pandey MK, Sethi G. Inflammation and cancer: how hot is the link? Biochem Pharmacol 2006; 72: 1605-21.
30. Jakobisiak M, Lasek W, Golab J. Natural mechanisms protecting against cancer. Immunol Lett 2003; 90: 103-22.
31. Markiewski MM, DeAngelis RA, Benencia F, Ricklin-Lichtsteiner SK, Koutoulaki A, Gerard C, Coukos G, Lambris JD. Modulation of the antitumor immune response by complement. Nat Immunol 2008; 9: 1225-35.
32. Markiewski MM, Lambris JD. Is complement good or bad for cancer patients? A new perspective on an old dilemma Trends Immunol 2009; 30: 286-92.
33. Alvarez RH, Kantarjian HM, Cortes JE. Biology of platelet-derived growth factor and its involvement in disease. Mayo Clin Proc 2006; 81: 1241-57.
34. Moustakas A, Pardali K, Gaal A, Heldin CH. Mechanisms of TGF-beta signaling in regulation of cell growth and differentiation. Immunol Lett 2002; 82: 85-91.